SU2C-ACS Lung Cancer Dream Team: Targeting KRAS Mutant Lung Cancers


Jeffrey A. Engelman, MD, PhD

Jeffrey A. Engelman, MD, PhD
Director, Center for Thoracic Cancers Massachusetts General Hospital Cancer Center; Associate Professor of Medicine, Harvard Medical School


Jedd D. Wolchok, MD, PhD

Jedd D. Wolchok, MD, PhD
Chief, Melanoma and Immunotherapeutics Service, Lloyd J. Old Chair for Clinical Investigation, Memorial Sloan Kettering Cancer Center


Lung cancer is the leading cause of cancer death in the United States. Mutations in the KRAS gene are found in 20 to 25 percent of lung cancers. These cancers do not respond well to standard lung cancer treatments and are notoriously difficult to treat. Fortunately, researchers are developing new drugs that specifically target biological pathways disrupted by mutant KRAS. In addition, a new class of drugs called immune checkpoint inhibitors has shown promising results in advanced lung cancer. However, there is now a critical need for laboratory and clinical investigations to determine how to optimize and integrate targeted and immune approaches into effective and unified treatment regimens for patients with KRAS-mutant lung cancer.

The SU2C-ACS Lung Cancer Dream Team is composed of some of the best lung cancer researchers and clinicians, along with leading immunologists and experts on KRAS. Several team members have been at the forefront of developing new, targeted therapies specifically designed for KRAS-mutant lung cancers while immunologists on the team have been leaders in developing therapies that harness the patients' own immune system to fight cancer.

The team will establish a collaborative, scientifically rigorous, multidisciplinary program that brings together the two highly promising treatment approaches of targeted therapy and immunotherapy. This combined KRAS targeted, immunotherapy approach should lead to novel therapies that will markedly improve outcomes for patients.

The team has devised a three-pronged approach to create new treatments for patients with KRAS-mutant lung cancers. First, the researchers will identify the most effective therapies for targeting KRAS and other related biological pathways. Second, they will develop approaches to exploit the immune system for the treatment of KRAS-mutant lung cancers. Third, they will integrate targeted therapies with immunotherapies as a novel combined approach to treatment of KRAS-mutant lung cancer.

Amount Of Funding:

$20,000,000 over a three-year period


John V. Heymach, MD, PhD, MD Anderson Cancer Center
Julie R. Brahmer, MD, Johns Hopkins Sidney Kimmel Cancer Center
Pasi A. Janne, MD PhD, Dana-Farber Cancer Institute
Roy S. Herbst, MD PhD, Yale University
Frank McCormick, PhD, University of California, San Francisco
David R. Gandara, MD, University of California, Davis
Charles M. Rudin, MD, PhD, Memorial Sloan Kettering Cancer Center


Andrea Ferris, MBA
Jeffrey Wigbels, MBA